{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T07:55:31Z","timestamp":1793778931590,"version":"4.6.1"},"reference-count":31,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1,11]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Plasmablastic lymphoma (PBL) is a rare and aggressive non-Hodgkin lymphoma associated with immunodeficiency, characterized by uncertain treatment approaches and an unfavorable prognosis. We conducted a multicenter, international, retrospective cohort study, aiming to characterize the clinical features, risk factors, and outcomes of patients with PBL. Data were collected from 22 institutions across 4 countries regarding patients diagnosed with PBL between 1 January 1999 and 31 December 2020. Survival risk factors were analyzed using both univariate and multivariate regression models. Overall survival (OS) was calculated using Kaplan-Meier statistics. First-line treatment regimens were stratified into standard- and higher-intensity regimens, and based on whether they incorporated a proteasome inhibitor (PI). A total of 281 patients (median age, 55 years) were included. Immunodeficiency of any kind was identified in 144 patients (51%), and 99 patients (35%) had HIV-positive results. The 5-year OS for the entire cohort was 36% (95% confidence interval, 30%-42%). In multivariate analysis, inferior OS was associated with Epstein-Barr virus\u2013negative lymphoma, poor performance status, advanced stage, and bone marrow involvement. In an independent univariate analysis, the international prognostic index was associated with OS outcomes. Neither immunosuppression nor HIV infection, specifically, influenced OS. Among patients treated with curative intent (n\u00a0= 234), the overall response rate was 72%. Neither the intensity of the treatment regimen nor the inclusion of PIs in first-line therapy was associated with OS. In this large retrospective study of patients with PBL, we identified novel risk factors for survival. PBL remains a challenging disease with poor long-term outcomes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2023021348","type":"journal-article","created":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T20:11:17Z","timestamp":1697227877000},"page":"152-165","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":26,"title":["The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma"],"prefix":"10.1182","volume":"143","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9282-8619","authenticated-orcid":false,"given":"Pietro R.","family":"Di Ciaccio","sequence":"first","affiliation":[{"name":"1Department of Haematology, The Canberra Hospital, Garran, ACT, Australia"},{"name":"2College of Health and Medicine, Australian National University, Canberra, ACT, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark N.","family":"Polizzotto","sequence":"additional","affiliation":[{"name":"1Department of Haematology, The Canberra Hospital, Garran, ACT, Australia"},{"name":"3John Curtin School of Medical Research, Australian National University, Canberra, ACT, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Cwynarski","sequence":"additional","affiliation":[{"name":"4Department of Haematology, University College Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4727-1425","authenticated-orcid":false,"given":"Alina S.","family":"Gerrie","sequence":"additional","affiliation":[{"name":"5Centre for Lymphoid Cancer and Division of Medical Oncology, BC Cancer, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Burton","sequence":"additional","affiliation":[{"name":"6Department of Haematology, St James University Hospital, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4077-6351","authenticated-orcid":false,"given":"Mark","family":"Bower","sequence":"additional","affiliation":[{"name":"7National Centre for HIV Malignancy, Chelsea and Westminster Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Kuruvilla","sequence":"additional","affiliation":[{"name":"8Division of Oncology and Haematology, Princess Margaret Cancer Centre, The Princess Margaret Hospital, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3006-9725","authenticated-orcid":false,"given":"Silvia","family":"Montoto","sequence":"additional","affiliation":[{"name":"9Department of Haemato-oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3959-9730","authenticated-orcid":false,"given":"Pam","family":"McKay","sequence":"additional","affiliation":[{"name":"10Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6322-9254","authenticated-orcid":false,"given":"Christopher P.","family":"Fox","sequence":"additional","affiliation":[{"name":"11University Hospitals NHS Trust, Nottingham, United Kingdom"},{"name":"12School of Medicine, University of Nottingham, Nottingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3368-5176","authenticated-orcid":false,"given":"Samuel","family":"Milliken","sequence":"additional","affiliation":[{"name":"13Department of Haematology, St Vincent\u2019s Hospital, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4810-0783","authenticated-orcid":false,"given":"Awachana","family":"Jiamsakul","sequence":"additional","affiliation":[{"name":"14The Kirby Institute, University of New South Wales, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Osborne","sequence":"additional","affiliation":[{"name":"15Department of Haematology, Freeman Hospital, Newcastle upon Tyne NHS Foundation Trust, Newcastle-upon-Tyne, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham P.","family":"Collins","sequence":"additional","affiliation":[{"name":"16Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Manos","sequence":"additional","affiliation":[{"name":"17Department of Haematology, Flinders Medical Centre, Adelaide, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3294-1548","authenticated-orcid":false,"given":"Kim M.","family":"Linton","sequence":"additional","affiliation":[{"name":"18The Christie Hospital NHS Foundation Trust, Manchester, United Kingdom"},{"name":"19Manchester Cancer Research Centre, University of Manchester, Manchester, United Kingdom"},{"name":"20Manchester Academic Health Science Centre, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4863-4160","authenticated-orcid":false,"given":"Sunil","family":"Iyengar","sequence":"additional","affiliation":[{"name":"21The Royal Marsden NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shireen","family":"Kassam","sequence":"additional","affiliation":[{"name":"22King's College Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle Poon","family":"Limei","sequence":"additional","affiliation":[{"name":"23Department of Haematology, National University Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2020-0275","authenticated-orcid":false,"given":"David","family":"Kliman","sequence":"additional","affiliation":[{"name":"24Department of Haematology, Royal North Shore Hospital, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3725-3397","authenticated-orcid":false,"given":"Nicole","family":"Wong Doo","sequence":"additional","affiliation":[{"name":"25Department of Haematology, Concord Repatriation General Hospital, Sydney, NSW, Australia"},{"name":"26Faculty of Medicine, University of Sydney, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Watson","sequence":"additional","affiliation":[{"name":"27Department of Haematology, Liverpool Hospital, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Fedele","sequence":"additional","affiliation":[{"name":"28School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia"},{"name":"29Haematology Department, Monash Health, Clayton, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costas K.","family":"Yannakou","sequence":"additional","affiliation":[{"name":"30Department of Molecular Oncology and Cancer Immunology, Epworth Freemasons Hospital, Epworth HealthCare, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stewart","family":"Hunt","sequence":"additional","affiliation":[{"name":"31Department of Haematology, Royal Brisbane and Women\u2019s Hospital, Brisbane, QLD, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9289-1335","authenticated-orcid":false,"given":"Matthew","family":"Ku","sequence":"additional","affiliation":[{"name":"32Department of Haematology, St Vincent\u2019s Hospital, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie H.","family":"Sehn","sequence":"additional","affiliation":[{"name":"5Centre for Lymphoid Cancer and Division of Medical Oncology, BC Cancer, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Smith","sequence":"additional","affiliation":[{"name":"33Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Renshaw","sequence":"additional","affiliation":[{"name":"4Department of Haematology, University College Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Maxwell","sequence":"additional","affiliation":[{"name":"7National Centre for HIV Malignancy, Chelsea and Westminster Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Liu","sequence":"additional","affiliation":[{"name":"8Division of Oncology and Haematology, Princess Margaret Cancer Centre, The Princess Margaret Hospital, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3230-758X","authenticated-orcid":false,"given":"Rageshri","family":"Dhairyawan","sequence":"additional","affiliation":[{"name":"34Department of Infection and Immunity, Barts Health NHS Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme","family":"Ferguson","sequence":"additional","affiliation":[{"name":"10Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6965-3817","authenticated-orcid":false,"given":"Keir","family":"Pickard","sequence":"additional","affiliation":[{"name":"15Department of Haematology, Freeman Hospital, Newcastle upon Tyne NHS Foundation Trust, Newcastle-upon-Tyne, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3936-7569","authenticated-orcid":false,"given":"Daniel","family":"Painter","sequence":"additional","affiliation":[{"name":"33Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha","family":"Thakrar","sequence":"additional","affiliation":[{"name":"4Department of Haematology, University College Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin W.","family":"Song","sequence":"additional","affiliation":[{"name":"35Leukemia\/Bone Marrow Transplant Program of British Columbia and Division of Hematology, BC Cancer, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7929-1450","authenticated-orcid":false,"given":"Nada","family":"Hamad","sequence":"additional","affiliation":[{"name":"13Department of Haematology, St Vincent\u2019s Hospital, Sydney, NSW, Australia"},{"name":"26Faculty of Medicine, University of Sydney, Sydney, NSW, Australia"},{"name":"36School of Medicine, University of Notre Dame, Perth, WA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"7","key":"2024011116290361800_bib1","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/PAS.0000000000000234","article-title":"Clinicopathologic comparison of plasmablastic lymphoma in HIV-positive, immunocompetent, and posttransplant patients: single-center series of 25 cases and meta-analysis of 277 reported cases","volume":"38","author":"Morscio","year":"2014","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"2024011116290361800_bib2","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.clml.2011.03.008","article-title":"HIV-negative plasmablastic lymphoma: not in the mouth","volume":"11","author":"Castillo","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"15","key":"2024011116290361800_bib3","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1182\/blood-2014-10-567479","article-title":"The biology and treatment of plasmablastic lymphoma","volume":"125","author":"Castillo","year":"2015","journal-title":"Blood"},{"key":"2024011116290361800_bib4","author":"Swerdlow","year":"2017"},{"issue":"8","key":"2024011116290361800_bib5","doi-asserted-by":"crossref","first-page":"976","DOI":"10.3324\/haematol.2016.141978","article-title":"Immune-checkpoint expression in Epstein-Barr virus positive and negative plasmablastic lymphoma: a clinical and pathological study in 82 patients","volume":"101","author":"Laurent","year":"2016","journal-title":"Haematologica"},{"issue":"suppl 1","key":"2024011116290361800_bib6","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/ijlh.13863","article-title":"Plasmablastic lymphoma: an update","volume":"44","author":"Bailly","year":"2022","journal-title":"Int J Lab Hematol"},{"key":"2024011116290361800_bib7","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13045-015-0163-z","article-title":"Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients","volume":"8","author":"Loghavi","year":"2015","journal-title":"J\u00a0Hematol Oncol"},{"issue":"6","key":"2024011116290361800_bib8","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1080\/10428194.2017.1387912","article-title":"Survival of patients with CD20-negative variants of large B-cell lymphoma: an analysis of the National Cancer Data Base","volume":"59","author":"Qunaj","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2024011116290361800_bib9","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1093\/annonc\/mdw684","article-title":"Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA group","volume":"28","author":"Tchernonog","year":"2017","journal-title":"Ann Oncol"},{"issue":"3","key":"2024011116290361800_bib10","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1634\/theoncologist.2009-0304","article-title":"Prognostic factors in chemotherapy-treated patients with HIV-associated Plasmablastic lymphoma","volume":"15","author":"Castillo","year":"2010","journal-title":"Oncologist"},{"issue":"21","key":"2024011116290361800_bib11","doi-asserted-by":"crossref","first-page":"5270","DOI":"10.1002\/cncr.27551","article-title":"Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy","volume":"118","author":"Castillo","year":"2012","journal-title":"Cancer"},{"issue":"27","key":"2024011116290361800_bib12","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2024011116290361800_bib13","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/bjh.18399","article-title":"Clinicopathological characteristics and long-term outcomes of plasmablastic lymphoma in British Columbia","volume":"199","author":"Jessa","year":"2022","journal-title":"Br J Haematol"},{"key":"2024011116290361800_bib14","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12979-018-0130-y","article-title":"Immunosenescence and lymphomagenesis","volume":"15","author":"Mancuso","year":"2018","journal-title":"Immun Ageing"},{"issue":"14","key":"2024011116290361800_bib15","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A\u00a0predictive model for aggressive non-Hodgkin\u2019s lymphoma","volume":"329","author":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors P","year":"1993","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"2024011116290361800_bib16","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2015.65.6520","article-title":"CNS international prognostic index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"34","author":"Schmitz","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2024011116290361800_bib17","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.3324\/haematol.2020.251579","article-title":"Genetic lesions in MYC and STAT3 drive oncogenic transcription factor overexpression in plasmablastic lymphoma","volume":"106","author":"Garcia-Reyero","year":"2021","journal-title":"Haematologica"},{"issue":"11","key":"2024011116290361800_bib18","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/ajh.25955","article-title":"Survival analysis in treated plasmablastic lymphoma patients: a population-based study","volume":"95","author":"Florindez","year":"2020","journal-title":"Am J Hematol"},{"issue":"1","key":"2024011116290361800_bib19","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1158\/2643-3230.BCD-20-0051","article-title":"Genomic characterization of HIV-associated plasmablastic lymphoma identifies pervasive mutations in the JAK-STAT pathway","volume":"1","author":"Liu","year":"2020","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"2024011116290361800_bib20","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3324\/haematol.2011.043331","article-title":"Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1","volume":"97","author":"Ling","year":"2012","journal-title":"Haematologica"},{"issue":"6","key":"2024011116290361800_bib21","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s00277-016-2904-7","article-title":"Refractory plasmablastic lymphoma-a review of treatment options beyond standard therapy","volume":"96","author":"Pretscher","year":"2017","journal-title":"Ann Hematol"},{"issue":"34","key":"2024011116290361800_bib22","doi-asserted-by":"crossref","first-page":"e704","DOI":"10.1200\/JCO.2010.30.0038","article-title":"Patient with HIV-associated plasmablastic lymphoma responding to bortezomib alone and in combination with dexamethasone, gemcitabine, oxaliplatin, cytarabine, and pegfilgrastim chemotherapy and lenalidomide alone","volume":"28","author":"Bibas","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"2024011116290361800_bib23","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.3109\/10428194.2015.1016931","article-title":"Dramatic efficacy of low dose lenalidomide as single agent in a patient with refractory gastric non-human immunodeficiency virus-associated plasmablastic lymphoma","volume":"56","author":"Carras","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2024011116290361800_bib24","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1111\/bjh.18228","article-title":"Daratumumab with ifosfamide, carboplatin and etoposide for the treatment of relapsed plasmablastic lymphoma","volume":"198","author":"Dittus","year":"2022","journal-title":"Br J Haematol"},{"issue":"12","key":"2024011116290361800_bib25","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1200\/JCO.2012.46.9593","article-title":"Brentuximab vedotin demonstrates activity in a patient with plasmablastic lymphoma arising from a background of chronic lymphocytic leukemia","volume":"31","author":"Holderness","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2024011116290361800_bib26","doi-asserted-by":"crossref","first-page":"e006684","DOI":"10.1136\/jitc-2023-006684","article-title":"BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma","volume":"11","author":"Raghunandan","year":"2023","journal-title":"J\u00a0Immunother Cancer"},{"issue":"4","key":"2024011116290361800_bib27","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1182\/blood.V89.4.1413","article-title":"Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection","volume":"89","author":"Delecluse","year":"1997","journal-title":"Blood"},{"issue":"6","key":"2024011116290361800_bib28","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/bjh.13221","article-title":"Survival of AIDS-related diffuse large B-cell lymphoma, Burkitt lymphoma, and plasmablastic lymphoma in the German HIV Lymphoma Cohort","volume":"168","author":"Schommers","year":"2015","journal-title":"Br J Haematol"},{"issue":"1","key":"2024011116290361800_bib29","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3109\/10428194.2014.911867","article-title":"Plasmablastic lymphoma among human immunodeficiency virus-positive patients: results of a single center\u2019s experience","volume":"56","author":"Cattaneo","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"2024011116290361800_bib30","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.3109\/10428194.2015.1113281","article-title":"Plasmablastic lymphoma is treatable in the HAART era. A 10 year retrospective by the AIDS Malignancy Consortium","volume":"57","author":"Noy","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2024011116290361800_bib31","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/bjh.15156","article-title":"Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma","volume":"184","author":"Castillo","year":"2019","journal-title":"Br J Haematol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/2\/152\/2180210\/blood_bld-2023-021348-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/2\/152\/2180210\/blood_bld-2023-021348-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T16:30:29Z","timestamp":1704990629000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/143\/2\/152\/498327\/The-influence-of-immunodeficiency-disease-features"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,11]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,1,11]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023021348","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,11]]}}}